[ Lung Therapeutics raises $14.3M in Series B ]

Lung Therapeutics has raised $14.3 million in Series B funding.

Founded in 2013, Lung Therpeutics  is a pharmaceutical company which focused on niche, orphan drug indications in lung injury and disease.

The proceeds will support ongoing LTI-01 clinical trials in Australia and New Zealand, as well as development activities to advance the Company’s transformative drug for fibrosis, LTI-03.

Funding  Series B
Founded  2013
Country  USA
City  Austin, TX
Founder / CEO  James Brian Windsor
Deal Size  $14.3M
Investors  Bios Partners
 UT Horizon Fund
Previous Investors  Texas Venture Labs
 UT Horizon Fund